References
1.
Bower
H
, Björkholm
M
, Dickman
PW
, Höglund
M
, Lambert
PC
, Andersson
TM
. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population
. J Clin Oncol
. 2016
Aug
;34
(24
):2851
–7
.
[PubMed]
0732-183X2.
Hochhaus
A
, Larson
RA
, Guilhot
F
, Radich
JP
, Branford
S
, Hughes
TP
, et al.; IRIS Investigators
. Long-term outcomes of imatinib treatment for chronic myeloid leukemia
. N Engl J Med
. 2017
Mar
;376
(10
):917
–27
.
[PubMed]
0028-47933.
Bauer
RC
, Sänger
J
, Peschel
C
, Duyster
J
, von Bubnoff
N
. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment
. Clin Cancer Res
. 2013
Jun
;19
(11
):2962
–72
.
[PubMed]
1078-04324.
Milojkovic
D
, Nicholson
E
, Apperley
JF
, Holyoake
TL
, Shepherd
P
, Drummond
MW
, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
. Haematologica
. 2010
Feb
;95
(2
):224
–31
.
[PubMed]
0390-60785.
Tam
CS
, Kantarjian
H
, Garcia-Manero
G
, Borthakur
G
, O’Brien
S
, Ravandi
F
, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
. Blood
. 2008
Aug
;112
(3
):516
–8
.
[PubMed]
0006-49716.
Tiribelli
M
, Bonifacio
M
, Binotto
G
, Iurlo
A
, Cibien
F
, Maino
E
, et al. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
. Oncotarget
. 2018
Feb
;9
(18
):14219
–27
.
[PubMed]
1949-25537.
Garg
RJ
, Kantarjian
H
, O’Brien
S
, Quintás-Cardama
A
, Faderl
S
, Estrov
Z
, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
. Blood
. 2009
Nov
;114
(20
):4361
–8
.
[PubMed]
0006-49718.
Russo Rossi
A
, Breccia
M
, Abruzzese
E
, Castagnetti
F
, Luciano
L
, Gozzini
A
, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
. Haematologica
. 2013
Mar
;98
(3
):399
–403
.
[PubMed]
0390-60789.
Ibrahim
AR
, Paliompeis
C
, Bua
M
, Milojkovic
D
, Szydlo
R
, Khorashad
JS
, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
. Blood
. 2010
Dec
;116
(25
):5497
–500
.
[PubMed]
0006-497110.
Ribeiro
BF
, Miranda
EC
, Albuquerque
DM
, Delamain
MT
, Oliveira-Duarte
G
, Almeida
MH
, et al. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors—a single center experience
. Clinics (São Paulo)
. 2015
Aug
;70
(8
):550
–5
.
[PubMed]
1807-593211.
Ongoren
S
, Eskazan
AE
, Suzan
V
, Savci
S
, Erdogan Ozunal
I
, Berk
S
, et al. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature
. Hematology
. 2018
May
;23
(4
):212
–20
.
[PubMed]
1607-845412.
Tan
J
, Xue
M
, Pan
J
, et al. Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia patients. Acta Hematol 2019
; epub ahead of print13.
Lipton
JH
, Bryden
P
, Sidhu
MK
, Huang
H
, McGarry
LJ
, Lustgarten
S
, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
. Leuk Res
. 2015
Jan
;39
(1
):58
–64
.
[PubMed]
0145-2126© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.